|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for APOM |
 Gene summary |
| Basic gene Info. | Gene symbol | APOM |
| Gene name | apolipoprotein M | |
| Synonyms | G3a|HSPC336|NG20|apo-M | |
| Cytomap | UCSC genome browser: 6p21.33 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001256169.1, NM_019101.2,NR_045828.1, | |
| Description | NG20-like proteinalternative name: G3a, NG20protein G3a | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 606907 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000204444 | ||
| HPRD : 06068 | ||
| Vega : OTTHUMG00000031250 | ||
| Protein | UniProt: O95445 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_APOM | |
| BioGPS: 55937 | ||
| Pathway | NCI Pathway Interaction Database: APOM | |
| KEGG: APOM | ||
| REACTOME: APOM | ||
| Pathway Commons: APOM | ||
| Context | iHOP: APOM | |
| ligand binding site mutation search in PubMed: APOM | ||
| UCL Cancer Institute: APOM | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0033344 | cholesterol efflux | 16682745 | GO:0034445 | negative regulation of plasma lipoprotein particle oxidation | 16682745 |
| Top |
| Ligand binding site mutations for APOM |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R143 | F144C | BLCA | 1 | F63 | P65H | STAD | 1 | R143 | R143H | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for APOM |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F63 | P65H | -1.2904808 | R143 | R143H | -0.54955243 | R143 | F144C | -0.27292853 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for APOM from PDB |
| Top |
| Differential gene expression and gene-gene network for APOM |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for APOM |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for APOM |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of APOM go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GYM | (2R)-2,3-DIHYDROXYPROPYL TETRADECANOATE | 2wex | A | F63 | S1P | SPHINGOSINE 1-PHOSPHATE(1-) | 2yg2 | A | F63 | S1P | SPHINGOSINE 1-PHOSPHATE(1-) | 2yg2 | B | F63 R143 | MYR | MYRISTIC ACID | 2wew | A | R143 |
| Top |
| Conservation information for LBS of APOM |
| Multiple alignments for O95445 in multiple species |
| LBS | AA sequence | # species | Species | D118 | TEGRPDMKTDL | 2 | Mus musculus, Rattus norvegicus | D118 | TEGRPDMKTEL | 1 | Homo sapiens | E136 | GIMLKETGQGY | 2 | Mus musculus, Rattus norvegicus | E136 | GIMLNETGQGY | 1 | Homo sapiens | F39 | VDGKEFPEVHL | 1 | Homo sapiens | F39 | MDDTETPEPHL | 1 | Mus musculus | F39 | MDDKETPEPHL | 1 | Rattus norvegicus | F63 | EELATFDPVDN | 2 | Homo sapiens, Mus musculus | F63 | EELATFDQVDN | 1 | Rattus norvegicus | F71 | VDNIVFNMAAG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H43 | ETPEPHLGLWY | 2 | Mus musculus, Rattus norvegicus | H43 | EFPEVHLGQWY | 1 | Homo sapiens | I132 | SCPGGIMLKET | 2 | Mus musculus, Rattus norvegicus | I132 | SCPGGIMLNET | 1 | Homo sapiens | I69 | DPVDNIVFNMA | 2 | Homo sapiens, Mus musculus | I69 | DQVDNIVFNMA | 1 | Rattus norvegicus | L111 | -GSTDLRTEGR | 1 | Homo sapiens | L111 | KGNMELRTEGR | 1 | Mus musculus | L111 | KGNTELRTEGR | 1 | Rattus norvegicus | L123 | DMKTELFSSSC | 1 | Homo sapiens | L123 | DMKTDLFSSSC | 1 | Mus musculus | L123 | DMKTDLFSISC | 1 | Rattus norvegicus | L134 | PGGIMLKETGQ | 2 | Mus musculus, Rattus norvegicus | L134 | PGGIMLNETGQ | 1 | Homo sapiens | L82 | SAPRQLQLRAT | 2 | Mus musculus, Rattus norvegicus | L82 | SAPMQLHLRAT | 1 | Homo sapiens | L84 | PRQLQLRATIR | 2 | Mus musculus, Rattus norvegicus | L84 | PMQLHLRATIR | 1 | Homo sapiens | P40 | DGKEFPEVHLG | 1 | Homo sapiens | P40 | DDTETPEPHLG | 1 | Mus musculus | P40 | DDKETPEPHLG | 1 | Rattus norvegicus | R116 | LRTEGRPDMKT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R143 | GQGYQRFLLYN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R98 | GLCVPRKWIYH | 1 | Homo sapiens | R98 | GVCVPRKWTYR | 1 | Mus musculus | R98 | GVCVPRKWTYH | 1 | Rattus norvegicus | W100 | CVPRKWIYHLT | 1 | Homo sapiens | W100 | CVPRKWTYRLT | 1 | Mus musculus | W100 | CVPRKWTYHLT | 1 | Rattus norvegicus | W47 | PHLGLWYFIAG | 2 | Mus musculus, Rattus norvegicus | W47 | VHLGQWYFIAG | 1 | Homo sapiens | Y102 | PRKWIYHLTE- | 1 | Homo sapiens | Y102 | PRKWTYRLTEG | 1 | Mus musculus | Y102 | PRKWTYHLTEG | 1 | Rattus norvegicus | Y141 | ETGQGYQRFLL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y147 | QRFLLYNRSPH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |